298 related articles for article (PubMed ID: 28683602)
21. The levonorgestrel-releasing intrauterine system and endometriosis staging.
Gomes MK; Ferriani RA; Rosa e Silva JC; Japur de Sá Rosa e Silva AC; Vieira CS; Cândido dos Reis FJ
Fertil Steril; 2007 May; 87(5):1231-4. PubMed ID: 17292364
[TBL] [Abstract][Full Text] [Related]
22. Long-term efficacy and safety of levonorgestrel releasing intrauterine system in the treatment of adenomyosis: evidence mapping.
Shi J; Gu Z; Wu Y; Li X; Zhang J; Zhang C; Yan H; Dai Y; Leng J
Arch Gynecol Obstet; 2024 Jul; 310(1):55-67. PubMed ID: 38836931
[TBL] [Abstract][Full Text] [Related]
23. Control of endometriosis-associated pain with etonogestrel-releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial.
Carvalho N; Margatho D; Cursino K; Benetti-Pinto CL; Bahamondes L
Fertil Steril; 2018 Nov; 110(6):1129-1136. PubMed ID: 30396557
[TBL] [Abstract][Full Text] [Related]
24. Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study.
Vercellini P; Frontino G; De Giorgi O; Aimi G; Zaina B; Crosignani PG
Fertil Steril; 2003 Aug; 80(2):305-9. PubMed ID: 12909492
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the hemostatic effects of a levonorgestrel-releasing intrauterine system and leuprolide acetate in women with endometriosis: a randomized clinical trial.
Yamaguti EM; Brito MB; Ferriani RA; Garcia AA; Rosa-e-Silva JC; Vieira CS
Thromb Res; 2014 Dec; 134(6):1193-7. PubMed ID: 25283586
[TBL] [Abstract][Full Text] [Related]
26. [A prospective cohort study on effects of levonorgestrel-releasing intrauterine system for adenomyosis with severe dysmenorrhea].
Li L; Leng JH; Dai Y; Zhang JJ; Jia SZ; Li XY; Shi JH; Zhang JR; Li T; Xu XX; Liu ZZ; You SS; Chang XY; Lang JH
Zhonghua Fu Chan Ke Za Zhi; 2016 May; 51(5):345-51. PubMed ID: 27256441
[TBL] [Abstract][Full Text] [Related]
27. [Levonorgestrel-releasing intrauterine system for treatment of dysmenorrhea associated with adenomyosis].
Sheng J; Lu D; Zhang JP; Cui GF
Zhonghua Fu Chan Ke Za Zhi; 2006 Jul; 41(7):467-70. PubMed ID: 17083813
[TBL] [Abstract][Full Text] [Related]
28. The efficacy of long-term maintenance therapy with a levonorgestrel-releasing intrauterine system for prevention of ovarian endometrioma recurrence.
Kim ML; Cho YJ; Kim MK; Jung YW; Yun BS; Seong SJ
Int J Gynaecol Obstet; 2016 Sep; 134(3):256-9. PubMed ID: 27346551
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy and impact on quality of life of different drug treatments after partial resection of rectovaginal endometriosis].
Li T; Xu XX; Dai Y; Zhang JJ; Lang JH; Leng JH
Zhonghua Fu Chan Ke Za Zhi; 2017 May; 52(5):307-313. PubMed ID: 28545268
[No Abstract] [Full Text] [Related]
30. Postoperative levonorgestrel-releasing intrauterine system for pelvic endometriosis-related pain: a randomized controlled trial.
Tanmahasamut P; Rattanachaiyanont M; Angsuwathana S; Techatraisak K; Indhavivadhana S; Leerasiri P
Obstet Gynecol; 2012 Mar; 119(3):519-26. PubMed ID: 22314873
[TBL] [Abstract][Full Text] [Related]
31. Effects of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers in patients with endometriosis: a comparative study with the GnRH analogue.
Ferreira RA; Vieira CS; Rosa-E-Silva JC; Rosa-e-Silva AC; Nogueira AA; Ferriani RA
Contraception; 2010 Feb; 81(2):117-22. PubMed ID: 20103448
[TBL] [Abstract][Full Text] [Related]
32. Effects of the levonorgestrel-releasing intrauterine system on cell proliferation, Fas expression and steroid receptors in endometriosis lesions and normal endometrium.
Gomes MK; Rosa-e-Silva JC; Garcia SB; de Sá Rosa-e-Silva AC; Turatti A; Vieira CS; Ferriani RA
Hum Reprod; 2009 Nov; 24(11):2736-45. PubMed ID: 19661125
[TBL] [Abstract][Full Text] [Related]
33. Uterine ultrasonographic changes during endometriosis treatment: a comparison between levonorgestrel-releasing intrauterine devices and a gonadotropin-releasing hormone agonist.
Manetta LA; de Paula Martins W; Rosa e Silva JC; de Sá Rosa e Silva AC; Nogueira AA; Ferriani RA
Ultrasound Med Biol; 2008 Dec; 34(12):1914-8. PubMed ID: 18597921
[TBL] [Abstract][Full Text] [Related]
34. Role of levonorgestrel-releasing intrauterine system in dysmenorrhea due to adenomyosis and the influence on ovarian function.
Ji F; Yang XH; Ai Xing Zi AL; Ha Ni Ke Zi TX; He Y; Ding Y
Clin Exp Obstet Gynecol; 2014; 41(6):677-80. PubMed ID: 25566593
[TBL] [Abstract][Full Text] [Related]
35. Effect of intracervical anesthesia on pain associated with the insertion of the levonorgestrel-releasing intrauterine system in women without previous vaginal delivery: a RCT.
Castro TV; Franceschini SA; Poli-Neto O; Ferriani RA; Silva de Sá MF; Vieira CS
Hum Reprod; 2014 Nov; 29(11):2439-45. PubMed ID: 25240012
[TBL] [Abstract][Full Text] [Related]
36. Effects of levonorgestrel-releasing intrauterine system and T380A intrauterine copper device on dysmenorrhea and days of bleeding in women with and without adenomyosis.
Kelekci S; Kelekci KH; Yilmaz B
Contraception; 2012 Nov; 86(5):458-63. PubMed ID: 22832203
[TBL] [Abstract][Full Text] [Related]
37. Clinical experiences of the levonorgestrel-releasing intrauterine system in patients with large symptomatic adenomyosis.
Park DS; Kim ML; Song T; Yun BS; Kim MK; Jun HS; Seong SJ
Taiwan J Obstet Gynecol; 2015 Aug; 54(4):412-5. PubMed ID: 26384061
[TBL] [Abstract][Full Text] [Related]
38. Use of the levonorgestrel intrauterine system in adolescents with endometriosis.
Yoost J; LaJoie AS; Hertweck P; Loveless M
J Pediatr Adolesc Gynecol; 2013 Apr; 26(2):120-4. PubMed ID: 23518190
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of the levonorgestrel-releasing intrauterine device in the treatment of recurrent pelvic pain in multitreated endometriosis.
Matorras R; Ballesteros A; Prieto B; Ocerin I; Expósito A; Pijoan JI; Crisol L
J Reprod Med; 2011; 56(11-12):497-503. PubMed ID: 22195333
[TBL] [Abstract][Full Text] [Related]
40. Endometriosis-associated pain scores and biomarkers in users of the etonogestrel-releasing subdermal implant or the 52-mg levonorgestrel-releasing intrauterine system for up to 24 months.
Margatho D; Carvalho NM; Bahamondes L
Eur J Contracept Reprod Health Care; 2020 Apr; 25(2):133-140. PubMed ID: 32069126
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
